Contemporary Spine Surgery Series: Making Sense of Bone Graft Alternatives (Excluding BMPs)

Confused by the overwhelming array of bone graft alternatives? Dr. Chris Ames presents an outstanding overview of the options.

Christopher P. Ames, MD presents the development and evolution of bone graft including allograft, synthetics, stems cells, and others. His discussion includes available data, outcomes and guidelines for patient and graft selection.

Release Date: July 22, 2009
Expiration Date: July 22, 2010

Faculty

  • Christopher P. Ames, MD About

    Associate Professor of Clinical Neurological Surgery
    Director of Spine Tumor and Spinal Deformity Surgery
    Co-director, Spinal Surgery and UCSF Spine Center
    Director, Spinal Biomechanics Laboratory

     

     UCSF Spine Center
    San Francisco, CA

      Doctor Christopher Ames is Director of Spinal Tumor and Spinal Deformity Surgery and is Co-director of the Neurospinal Disorders Program and the University of California at San Francisco (UCSF) Spine Center. He is also Director of the Spine Tumor and Deformity fellowship program. He is board-certified in neurosurgery.    Read More

Target Audience

The online continuing education program is intended for orthopaedic and neurological surgeons, residents, and fellows who include spinal surgery in their practices.

Educational Objectives

  • Discuss the history of bone graft including autograft, allograft, DBM (demineralized bone matrix), BMP (bone morphogenetic protein), synthetic bone substitutes, and allograft/stem cells.
  • Describe assays and supporting literature; bone graft use and outcomes.
  • Discuss procedure changes associated with patient age, revision rates, graft selection and implantation.

Course Completion Time

Based upon trials, the estimated time to complete this program is 0.5 hour.

Sponsorship

This activity is sponsored by Medical Education Resources, Inc., a non-profit medical education company. BroadWater, a Vertical Health, LLC company, was selected to manage program development logistics.

Educational Grant

This activity received a restricted educational grant from K2M, Inc.

Physician Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medical Education Resources and BroadWater. Medical Education Resources is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Medical Education Resources designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Policy

It is the policy of Medical Education Resources (MER) to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty/ authors participating in our programs are expected to disclose any relationships they may have with commercial companies whose products or services may be mentioned so that participants may evaluate the objectivity of the presentations.

Faculty Disclosure

In accordance with U.S. Food and Drug Administration (FDA) and ACCME guidelines, the financial and significant relationships to this program are listed below.

Christopher P. Ames, MD has indicated the following relevant financial relationships: ApaTech™: Grants/Research Support and NuVasive®: Consultant

Staff Disclosure

Jeremy Longhurst, Susan Spinasanta: Nothing to disclose.

The staff at MER has nothing to disclose.

Advisor/Staff Disclosures
Jason M. Highsmith, MD: Speakers Bureau: Boston Scientific, Globus Medical

Disclaimer

The content and views presented in this educational activity are those of the faculty and do not necessarily reflect those of Medical Education Resources.

A restricted educational grant in support of this program was provided by: K2M, Inc.

Purpose
This program is for educational and scientific purposes only. Any discussion
of a product will be objective, balanced, and scientifically rigorous.

Off-Label/Investigational Use

It should be noted that specific medicines and medical devices discussed or referred to in this program may not yet be specifically cleared by the FDA for use in the United States. It is emphasized that package inserts must be referred to for labeling limitations for products used in the United States.

Software Requirements